1. Cook JR, Isaacson PG, Chott A, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, et al., Herausgeber. WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4). Lyon: IARC; 2017. S. 259–62.
2. Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow S, Campo E, Harris NL, et al., Herausgeber. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. S. 214–7.
3. Raderer M, Wohrer S, Kiesewetter B, et al. Antibiotic treatment as sole management of helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up. Ann Hematol. 2015;94:969–73.
4. Wohrer S, Kiesewetter B, Fischbach J, et al. Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. Ann Hematol. 2014;93:1287–95.
5. Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus Chlorambucil versus either Chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35:1905–12.